ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2020

9:00AM-11:00AM: Abstract Number: 1155

Long-term Safety Profile of Anakinra in Patients with Systemic Juvenile Idiopathic Arthritis

Pediatric Rheumatology – Clinical Poster II: Systemic JIA, Autoinflammatory, & Scleroderma

9:00AM-11:00AM: Abstract Number: 1392

Long-Term Tolerability of Aminaphtone in Raynaud’s Phenomenon Secondary to Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 1003

Long-term Weight Changes and Risk of Rheumatoid Arthritis Among Women in a Prospective Cohort: A Marginal Structural Model Approach

Epidemiology & Public Health Poster III: Inflammatory Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 1299

Longitudinal Patterns of Anxiety Symptomology Among Patients with Systemic Lupus Erythematosus (SLE) Remain Stable over Time and Do Not Associate with SLE Disease Activity

SLE – Diagnosis, Manifestations, & Outcomes Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1260

Longitudinal Relationships Between Depression, Anxiety and Cognition in Lupus

SLE – Diagnosis, Manifestations, & Outcomes Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1114

Longitudinally Assessed Structural Abnormalities on MRI and Relative Contributions to Risk of Incident Radiographic Knee Osteoarthritis over 10 Years of Follow-up

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 1277

Low Cost Composite Markers to Differentiate Infection from Disease Activity in a Febrile Patient with Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: PP02

Low- and Hi-Tech Tools for Enhancing Patient-Hospital Care Team Communication in the Context of Rare Disease

Patient Perspectives Poster

9:00AM-11:00AM: Abstract Number: 1297

Lupus Antibodies in Relation to Malignancy

SLE – Diagnosis, Manifestations, & Outcomes Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1298

Lupus Damage Free-Survival by Age at Diagnosis: A Retrospective Incident Lupus Cohort

SLE – Diagnosis, Manifestations, & Outcomes Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1365

Machine Learning-based Berlin Scoring of Magnetic Resonance Images of the Spine in Patients with Ankylosing Spondylitis: Analysis of Data from a Phase 3 Trial with Secukinumab

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

9:00AM-11:00AM: Abstract Number: 1116

Magnetic Resonance Imaging Structural Changes Correlated with Knee Extension: Data from the Osteoarthritis Initiative

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 1326

Malignancy Risk Among Patients with Ankylosing Spondylitis in the United States: A Population-Based National Study

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Extra-MSK & Comorbidities

9:00AM-11:00AM: Abstract Number: 1256

Mast Cells Contribute to the Development of Sialadenitis Associated with Sjögren’s Syndrome via Inducing Tissue Fibrosis by TGFβ Production

Sjögren’s Syndrome Poster

9:00AM-11:00AM: Abstract Number: 1437

Measuring Disease Activity and Functional Status in Patients with Granulomatosis with Polyangiitis (Wegener’s) (GPA)

Vasculitis – ANCA-Associated Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.